CROSS-SPECIES-SPECIFIC PSCA×CD3, CD19×CD3, C-MET×CD3, ENDOSIALIN×CD3, EpCAM×CD3, IGF-1R×CD3, OR FAPα×CD3 BISPECIFIC SINGLE CHAIN ANTIBODY

• Main Authors: RALF LUTTERBUESE, TOBIAS RAUM, KUFER PETER, DORIS RAU, MATTHIAS KLINGER, CLAUDIA BLUEMEL, ROMAN KISCHEL, SUSANNE MANGOLD, PATRIK HOFFMANN
• Format: Patent
• Language: English; Japanese
• Published: 26.04.2018
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

PROBLEM TO BE SOLVED: To solve the problem in which the species specificity of monoclonal antibodies is a significant impediment in their development as human therapeutic agents, and to provide a cross-species-specific antibodies for CD3.SOLUTION: The present invention relates to a bispecific single chain antibody molecule comprising: a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, where the epitope is part of a specific amino acid sequence; and a second binding domain capable of binding to an antigen selected from among prostate stem cell antigen (PSCA), B-lymphocyte antigen CD19 (CD19), hepatocyte growth factor receptor (C-MET), endosialin, the EGF-like domain 1 of EpCAM encoded by exon 2, fibroblast activation protein α (FAPα) and insulin-like growth factor I receptor (IGF-IR or IGF-1R).SELECTED DRAWING: None 【課題】モノクローナル抗体の種特異性は、それらをヒト治療剤として開発する上で重大な障害である。ＣＤ３に対する異種間特異的抗体の提供。【解決手段】特定のアミノ酸配列の一部であり、ヒト及び非チンパンジー霊長動物のＣＤ３イプシロン鎖のエピトープに結合することが可能な第１の結合ドメインと、前立腺幹細胞抗原（ＰＳＣＡ）、Ｂリンパ球抗原ＣＤ１９（ＣＤ１９）、肝細胞増殖因子受容体（Ｃ−ＭＥＴ）、エンドシアリン、エクソン２によりコードされるＥｐＣＡＭのＥＧＦ様ドメイン１、線維芽細胞活性化タンパク質アルファ（ＦＡＰアルファ）、及びインスリン様増殖因子Ｉ受容体（ＩＧＦ−ＩＲまたはＩＧＦ−１Ｒ）から選択される抗原に結合することが可能な第２の結合ドメインとを含む二重特異性単鎖抗体分子。【選択図】なし